SEC Form 4 · accession 0001628280-26-054941
Skye Bioscience, Inc. · SKYE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Punit Dhillon
Officer — Chief Executive Officer · Director
Period of report
Aug 7, 2026
Accepted (ET)
Aug 7, 2026 · 5:37 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001516551
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Aug 7, 2026 | A | 1,090,000 | $0.00 | A | 1,419,823 | D | |
| Common Stock | holding | — | — | — | 9,343 | I | Trust |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Represents a restricted stock unit ("RSU") award that will vest on August 31, 2027 subject to (a) the Reporting Person's continued employment through such date or (b) the termination of the Reporting Person's employment by the Company for any reason other than For Cause, By Death or By Disability (each, as defined in the Reporting Person's Executive Employment Agreement), provided the Reporting Person executes and does not revoke the release agreement appended to the Reporting Person's Executive Employment Agreement.
- F2Each RSU represents a contingent right to receive one share of the Issuer's common stock.